Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection

被引：12

作者：

Verburg, Frederik A. ^{[1
]}

de Blois, Erik ^{[1
]}

Koolen, Stijn ^{[1
,2
,3
]}

Konijnenberg, Mark W. ^{[1
,4
]}

机构：

[1] Erasmus MC, Dept Radiol & Nucl Med, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands

[2] Erasmus MC, Dept Hosp Pharm, Rotterdam, Netherlands

[3] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands

[4] Radboud UMC, Dept Radiol & Nucl Med, Nijmegen, Netherlands

来源：

EJNMMI PHYSICS | 2023年 / 10卷 / 01期

关键词：

Lu-177]Lu-DOTA-TATE; Lu-177]Lu-PSMA-617; Radionuclide therapy; Dosimetry; Terbium-161; PRRT;

D O I：

10.1186/s40658-023-00589-w

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Aim: To explore the dosimetric effect of substituting Lu-177 with Tb-161 in targeted radionuclide therapy (TRT) using the registered tracers DOTA-TATE and PSMA-617.Methods: Using established kinetic data for [Lu-177]Lu-DOTA-TATE and [Lu-177]Lu-PSMA-617, radiation absorbed doses to typical tumour lesion as well as non-target tissues ([Lu-177]Lu-DOTA-TATE: kidneys, spleen and liver, [Lu-177]Lu-PSMA-617: kidneys, liver and salivary glands) were calculated for Lu-177 and Tb-161.Results: For both DOTA-TATE and PSMA-617, the substitution of Lu-177 with Tb-161 results in an increase in the delivered dose per unit of activity to tumour tissue by 40%. If an equivalent non-target delivered dose is strived for in order not to increase toxicity, based on kidney absorbed dose, 7400 MBq Lu-177 per cycle should be substituted with 5400 MBq Tb-161 for DOTA-TATE and 5300 MBq of Tb-161 for PSMA-617.Conclusion: When substituting Lu-177 with Tb-161, activity conversion is necessary in order not to exceed non-target dose limits.

引用

页数：6